ClinConnect ClinConnect Logo
Search / Trial NCT06871826

Tissue Inhibitor of Metalloproteinases 2 Level in Patients Undergoing Cardiac Surgery

Launched by WUHAN UNIVERSITY · Mar 7, 2025

Trial Information

Current as of April 23, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients (≥18 years old) underwent on-pump cardiac surgery
  • admitted to ICU immediately after surgery
  • Exclusion Criteria:
  • Patients younger than 18 years
  • with prior AKI
  • end-stage kidney disease
  • need for chronic hemodialysis
  • pregnant patients
  • unable to give written consent for participation

About Wuhan University

Wuhan University, a prestigious research institution located in Wuhan, China, is renowned for its commitment to advancing medical science and improving public health through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive academic resources and expertise to conduct rigorous clinical studies aimed at exploring novel therapies and interventions. The institution is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and well-being of participants while contributing valuable insights to the global medical community.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported